Molecular Formula | C18H16N4O3S |
Molar Mass | 368.41 |
Density | 1.394 |
Melting Point | 247-249°C |
Boling Point | 568.4±50.0 °C(Predicted) |
Solubility | Soluble in DMSO (40 mg/ml) |
Appearance | powder |
Color | white to beige |
pKa | 9.97±0.70(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
In vitro study | VE-821 acts on ATR with excellent selectivity, and acts on related PIKKs ATM, DNA-PK, mTOR and PI3K with the lowest cross-reactivity, Ki is 16 μm, 2.2 μm, >1 M and 3.9 M. VE-821 alone, it kills most of the cancer cell population, but acts on normal cells to reversibly restrict cell cycle progression, producing minimal death or long-term deleterious effects. The combination of VE-821 and Cisplatin had the most significant synergistic effect. VE-821 inhibit H2AX cell growth with an IC50 of 800 nM. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.714 ml | 13.572 ml | 27.144 ml |
5 mM | 0.543 ml | 2.714 ml | 5.429 ml |
10 mM | 0.271 ml | 1.357 ml | 2.714 ml |
5 mM | 0.054 ml | 0.271 ml | 0.543 ml |
biological activity | VE-821 is a potent, selective, ATP-competitive inhibitor of ATR, A Ki/IC50 of 13 nM/26 nM inhibits H2AX phosphorylation with minimal inhibitory activity on PIKKs ATM, DNA-PK, mTOR and PI3Kγ. |